CerbB-2、P53、ER、PR在乳腺癌中的表达及临床意义

Expressions and clinical significances of CerbB-2、P53、ER and PR in breast cancer

目的联合检测CerbB-2、P53、ER、PR在乳腺癌中的表达并探讨其临床意义。方法采用免疫组化S-P法分别检测87例乳腺癌和20例正常乳腺组织CerbB-2、P53、ER、PR的表达。结果87例乳腺癌CerbB-2、P53、ER、PR阳性表达率分别为36.8%,28.7%,66.7%,51.7%。与正常乳腺组织比较,CerbB-2、P53的阳性表达有差异(P<0.05),ER、PR的阳性表达无差异(P>0.05);CerbB-2、P53阳性表达与肿瘤大小无相关性(P>0.05),与组织学分级、有无淋巴结转移和有无复发有相关性(P<0.05);ER、PR阳性表达与肿瘤大小,组织学分级、有无淋巴结转移和有无复发均无相关性(P>0.05)。CerbB-2和P53共同表达与有无淋巴结转移、有无复发有相关性(P<0.05)。结论联合检测CerbB-2、P53、ER、PR的表达对乳腺癌的临床及预后都有一定意义。

Objective To detect the expressions of CerbB-2, P53, ER,PR in breast cancer and study its clinical significances. Methods Expressions of CerbB-2, P53, ER, PR in 87 cases of breast cancer and 20 cases of normal breast tissue were detected by using immunohistochemistry technique （S-P）. Results The rate of positive expressions of CerbB-2,P53 ,ER,PR were 36.8% ,28.7% ,66.7% ,51.7% respectively. Compared with normal cases, the positive expressions of CerbB-2,P53 in breast cancer tissue had statistical significance（ P 〈 0.05 ）. They also had close relationships with lymphatic metastasis,histology phase and recurrence rate （P 〈 0.05 ） and had no relationship with tumor size （P 〉 0.05 ）. The expression of both CerbB-2 and P53 had positive correlation with lymphatic metastasis and recurrence rate （ P 〈 0.05 ）. The expressions of ER,PR had no statistics significance compared with normal cases（ P 〉0.05 ）, and they had no relationship with lymphatic metastasis,histology phase,tumor size and recurrence rate（P 〉0.05 ）. Conclusion Combined detection of the expressions of CerbB-2 ,P53, ER and PR has some clinical and prognosis significances on breast cancer.